Mathes Company’s Gilead Sciences GILD Stock Holding History

Mathes Company’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$767K	Hold	5,500	–	–	0.28%	62
2025 Q4	$675K	Hold	5,500	–	–	0.24%	63
2025 Q3	$611K	Hold	5,500	–	–	0.22%	70
2025 Q2	$610K	Sell	5,500 -1,000	-15%	-$106K	0.23%	71
2025 Q1	$728K	Hold	6,500	–	–	0.3%	63
2024 Q4	$600K	Hold	6,500	–	–	0.22%	77
2024 Q3	$545K	Hold	6,500	–	–	0.19%	86
2024 Q2	$446K	Sell	6,500 -500	-7%	-$33.4K	0.16%	89
2024 Q1	$513K	Hold	7,000	–	–	0.19%	88
2023 Q4	$567K	Hold	7,000	–	–	0.23%	84
2023 Q3	$525K	Hold	7,000	–	–	0.24%	83
2023 Q2	$539K	Buy	+7,000	New	+$558K	0.24%	86
2022 Q4	$685K	Hold	7,975	–	–	0.35%	73
2022 Q3	$492K	Hold	7,975	–	–	0.27%	81
2022 Q2	$493K	Hold	7,975	–	–	0.24%	88
2022 Q1	$474K	Hold	7,975	–	–	0.18%	93
2021 Q4	$579K	Sell	7,975 -1,250	-14%	-$86.1K	0.2%	88
2021 Q3	$644K	Hold	9,225	–	–	0.24%	84
2021 Q2	$635K	Sell	9,225 -1,025	-10%	-$68.4K	0.23%	83
2021 Q1	$662K	Buy	10,250 +1,750	+21%	+$113K	0.26%	83
2020 Q4	$495K	Hold	8,500	–	–	0.2%	90
2020 Q3	$537K	Hold	8,500	–	–	0.25%	82
2020 Q2	$654K	Sell	8,500 -1,750	-17%	-$134K	0.33%	76
2020 Q1	$766K	Sell	10,250 -1,250	-11%	-$86.4K	0.51%	58
2019 Q4	$747K	Sell	11,500 -1,000	-8%	-$65.1K	0.35%	74
2019 Q3	$792K	Hold	12,500	–	–	0.41%	66
2019 Q2	$845K	Sell	12,500 -175	-1%	-$11.5K	0.45%	63
2019 Q1	$824K	Sell	12,675 -600	-5%	-$39.9K	0.42%	65
2018 Q4	$830K	Sell	13,275 -900	-6%	-$62.9K	0.52%	58
2018 Q3	$1.09M	Buy	14,175 +100	+0.7%	+$7.55K	0.51%	58
2018 Q2	$997K	Sell	14,075 -550	-4%	-$38.8K	0.48%	61
2018 Q1	$1.1M	Hold	14,625	–	–	0.52%	56
2017 Q4	$1.05M	Sell	14,625 -4,300	-23%	-$327K	0.48%	56
2017 Q3	$1.53M	Buy	18,925 +1,100	+6%	+$84.1K	0.72%	46
2017 Q2	$1.26M	Sell	17,825 -1,200	-6%	-$79.9K	0.6%	46
2017 Q1	$1.29M	Buy	19,025 +800	+4%	+$56.3K	0.69%	45
2016 Q4	$1.3M	Sell	18,225 -875	-5%	-$65K	0.72%	44
2016 Q3	$1.51M	Sell	19,100 -5,850	-23%	-$475K	0.86%	41
2016 Q2	$2.08M	Sell	24,950 -3,075	-11%	-$273K	1.21%	28
2016 Q1	$2.57M	Sell	28,025 -6,375	-19%	-$575K	1.55%	21
2015 Q4	$3.48M	Buy	34,400 +350	+1%	+$36.4K	1.98%	10
2015 Q3	$3.34M	Sell	34,050 -575	-2%	-$63.9K	2.21%	8
2015 Q2	$4.05M	Sell	34,625 -1,250	-3%	-$137K	2.17%	7
2015 Q1	$3.52M	Buy	35,875 +1,550	+5%	+$157K	1.81%	8
2014 Q4	$3.23M	Buy	34,325 +325	+1%	+$33.6K	1.69%	9
2014 Q3	$3.62M	Buy	34,000 +1,025	+3%	+$100K	1.82%	9
2014 Q2	$2.73M	Buy	32,975 +3,425	+12%	+$267K	1.35%	13
2014 Q1	$2.09M	Buy	29,550 +2,500	+9%	+$196K	1.12%	28
2013 Q4	$2.03M	Buy	27,050 +19,950	+281%	+$1.39M	1.09%	33
2013 Q3	$446K	Buy	7,100 +800	+13%	+$47.8K	0.43%	59
2013 Q2	$323K	Buy	+6,300	New	+$328K	0.35%	64

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Mathes Company's GILD Position: Q1 2026 in Review

Mathes Company held its Gilead Sciences (GILD) position steady in Q1 2026 at 5,500 shares worth $767K. The position accounts for 0.28% of the portfolio, ranked #62.

Mathes Company first reported a position in GILD in Q2 2013 and has held it in 51 quarters since. The position peaked at $4.05M in Q2 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Mathes Company held 5,500 shares of Gilead Sciences worth $767K as of Q1 2026.
Mathes Company left its Gilead Sciences share count unchanged in Q1 2026.
Gilead Sciences made up 0.28% of Mathes Company's portfolio in Q1 2026, its #62 holding.
Mathes Company first reported a position in Gilead Sciences in Q2 2013 and has held it in 51 quarters since.
Mathes Company's Gilead Sciences position peaked at $4.05M in Q2 2015.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Mathes Company's 13F filing for Q1 2026, filed 8 May 2026.